Hoth Therapeutics Says Interim Trial Results Show Drug to Mitigate Skin Cancer Treatment Toxicity Met Efficacy Endpoint

MT Newswires Live

2025/01/07

Hoth Therapeutics (HOTH) said Tuesday interim results from a phase 2a trial of HT-001 showed that all patients met the primary efficacy endpoint.

The trial demonstrated improvements in skin toxicities caused by epidermal growth factor receptor inhibitors, with all patients maintaining full cancer treatment doses, the company said.

Hoth reported no treatment-related adverse effects, noting HT-001's safety and tolerability.

The company's shares were up over 94% in recent early Tuesday trading.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2501200456"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501200456\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501200456?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501200456","market":"nz","top_or_hot":-1,"title":"Hoth Therapeutics Says Interim Trial Results Show Drug to Mitigate Skin Cancer Treatment Toxicity Met Efficacy Endpoint","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> (HOTH) said Tuesday interim results from a phase 2a trial of HT-001 showed that all patients met the primary efficacy endpoint.</p><p>The trial demonstrated improvements in skin toxicities caused by epidermal growth factor receptor inhibitors, with all patients maintaining full cancer treatment doses, the company said.</p><p>Hoth reported no treatment-related adverse effects, noting HT-001's safety and tolerability.</p><p>The company's shares were up over 94% in recent early Tuesday trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Says Interim Trial Results Show Drug to Mitigate Skin Cancer Treatment Toxicity Met Efficacy Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Says Interim Trial Results Show Drug to Mitigate Skin Cancer Treatment Toxicity Met Efficacy Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-07 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> (HOTH) said Tuesday interim results from a phase 2a trial of HT-001 showed that all patients met the primary efficacy endpoint.</p><p>The trial demonstrated improvements in skin toxicities caused by epidermal growth factor receptor inhibitors, with all patients maintaining full cancer treatment doses, the company said.</p><p>Hoth reported no treatment-related adverse effects, noting HT-001's safety and tolerability.</p><p>The company's shares were up over 94% in recent early Tuesday trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2501200456","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501200456","pubTimestamp":1736260960,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hoth Therapeutics  said Tuesday interim results from a phase 2a trial of HT-001 showed that all patients met the primary efficacy endpoint.The trial demonstrated improvements in skin toxicities caused by epidermal growth factor receptor inhibitors, with all patients maintaining full cancer treatment doses, the company said.Hoth reported no treatment-related adverse effects, noting HT-001's safety and tolerability.The company's shares were up over 94% in recent early Tuesday trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK1612":"加密货币概念","01611":"新火科技控股","BK1167":"电子制造服务","HOTH":"Hoth Therapeutics"},"translate_title":"Hoth Therapeutics表示，中期试验结果显示减轻皮肤癌治疗毒性的药物达到了疗效终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1,"01611":0.9},"content_text":"Hoth Therapeutics (HOTH) said Tuesday interim results from a phase 2a trial of HT-001 showed that all patients met the primary efficacy endpoint.The trial demonstrated improvements in skin toxicities caused by epidermal growth factor receptor inhibitors, with all patients maintaining full cancer treatment doses, the company said.Hoth reported no treatment-related adverse effects, noting HT-001's safety and tolerability.The company's shares were up over 94% in recent early Tuesday trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}